Berger C, de Muret A, Garaud P, Chapet S, Bourlier P, Reynaud-Bougnoux A, Dorval E, de Calan L, Huten N, Le Floch O, Calais G
Unité de traitement des cancers digestifs, clinique Sainte Catherine, BP 846, Avignon, France.
Cancer Radiother. 1997;1(3):240-8. doi: 10.1016/s1278-3218(97)89771-5.
To determine predictive factors and prognostic value of tumor downstaging and sterilization after preoperative radiotherapy for rectal cancer.
Between 1977 and 1994, 167 patients with a histologically proven adenocarcinoma underwent preoperative radiotherapy (median dose, 44 Gy; mean time before surgery, 5 weeks). Pathologic specimens were reviewed by the same pathologist in order to specify the modified Astler Coller classification (MAC) and to quantify residual tumor cell density (RTCD).
According to the MAC, there were nine stage 0 (5%), 10 stage A (6%), 103 stage B1-B3 (62%) and 45 stage C1-C3 (27%) tumors. Seventeen per cent and 56% of the patients who received a dose > or = 44 Gy presented with stage 0-A and stage B1-B3 tumors, respectively, compared to 4 and 69% of those who received a dose < 44 Gy (P = 0.04). Tumor differentiation and a longer interval before surgery were significantly associated with more frequent downstaging. According to the RTCD, 62 tumors (37%) showed no or only rare foci of residual tumor cells; 62 (37%) showed an intermediate RTCD and 43 (26%) a high RTCD. No predictive factor of RTCD was statistically significant. Only post-operative staging was a significant prognostic factor (P < 0.01).
The favourable influence of higher doses of preoperative radiotherapy on pathologic stage has been observed. Tumor differentiation and time before surgery were the other significant predictive factors of tumor downstaging. Even after preoperative radiotherapy, post-operative staging retained its prognostic value.
确定直肠癌术前放疗后肿瘤降期和肿瘤细胞清除的预测因素及预后价值。
1977年至1994年间,167例经组织学证实为腺癌的患者接受了术前放疗(中位剂量44 Gy;术前平均时间5周)。同一位病理学家对病理标本进行复查,以明确改良的阿斯特勒-科勒分类法(MAC)并量化残余肿瘤细胞密度(RTCD)。
根据MAC分类,有9例0期(5%)、10例A期(6%)、103例B1 - B3期(62%)和45例C1 - C3期(27%)肿瘤。接受剂量≥44 Gy的患者中,分别有17%和56%呈现0 - A期和B1 - B3期肿瘤,而接受剂量<44 Gy的患者中这一比例分别为4%和69%(P = 0.04)。肿瘤分化程度和术前间隔时间较长与更频繁的降期显著相关。根据RTCD,62例肿瘤(37%)显示无或仅有罕见的残余肿瘤细胞灶;62例(37%)显示RTCD中等,43例(26%)显示RTCD高。RTCD的预测因素均无统计学意义。只有术后分期是显著的预后因素(P < 0.01)。
已观察到较高剂量的术前放疗对病理分期有有利影响。肿瘤分化程度和术前时间是肿瘤降期的其他重要预测因素。即使经过术前放疗,术后分期仍保留其预后价值。